Scientific Advisory Board, Member

Beth Borowsky PhD
Director of Translational Medicine
Clinical Research
CHDI Management/CHDI Foundation

Beth Borowsky is the Director of Translational Medicine at CHDI Foundation.  She manages a portfolio of projects aimed at identifying biomarkers and endpoints for use in clinical trials in Huntington’s disease. Projects she has led include TRACK-HD, TRACK-On, the CHDI Cognitive Assessment Battery Beta and numerous imaging and wet biomarker studies.  Dr. Borowsky is a member of the FNIH Biomarker Consortium, and the Common Data Elements biomarker working group for Huntington’s disease. Prior to joining CHDI in 2007, Beth spent 13 years in CNS drug discovery and development with sanofi-aventis and Synaptic Pharmaceuticals (now Lundbeck), where she held positions of increasing responsibility. As the Schizophrenia Program Leader in the CNS Disease Group at Aventis, she developed a new strategy for developing therapeutics to treat the cognitive deficits associated with schizophrenia. Following the merger with Sanofi, she became an Associate Director, leading the US Psychopharmacology Group within the CNS Therapeutic Department. Beth began her career at Synaptic Pharmaceuticals where she identified, cloned and patented numerous novel G protein-coupled receptors (GPCR). By the time she left Synaptic, she had established the company’s first in vivo behavioral laboratories, was responsible for assessing novel GPCR targets for potential therapeutic indications as well as designing and implementing in vivo and in vitro screening strategies to promote lead compounds to Early Development Candidates. Beth received a BS in Psychology and Neurobiology from Rutgers University, and a PhD in Pharmacology from Duke University Medical Center. She completed her post-doctoral training at the National Institute of Mental Health.